Cocrystal Pharma (COCP) Return on Capital Employed (2011 - 2026)
Cocrystal Pharma (COCP) posted Return on Capital Employed of 142.49% for Q1 2026, down 24.32% sequentially from 114.61% in Q4 2025, and up 1611.0% YoY from 8.33% in Q1 2025.
Cocrystal Pharma (COCP) Return on Capital Employed (2011 - 2026) Analysis & Trends
Cocrystal Pharma has reported Return on Capital Employed for 14 years, with the latest figure at 142.49% in Q1 2026.
- Quarterly Return on Capital Employed rose 1611.0% year-over-year to 142.49% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 142.49% (up 1611.0% YoY) and the FY2025 annual result came in at 96.21%, down 651.0% from the prior year.
- Return on Capital Employed declined to 142.49% in Q1 2026 per COCP's latest filing, from 114.61% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 20.69% in Q1 2022 and troughed at 164.12% in Q2 2025.
- A 5-year average of 97.27% and a median of 92.39% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 4340 bps in 2024, then tumbled 9222 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 92.39% in 2022, then advanced by 30 bps to 64.72% in 2023, then slumped by 122 bps to 143.99% in 2024, then advanced by 20 bps to 114.61% in 2025, then fell by 24 bps to 142.49% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 142.49%, 114.61%, and 122.78% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Cocrystal Pharma | 15.65 Mn | 13.33 Mn | - | -295.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -295.48% |
| Mar 31, 2026 | -142.49% |
| Dec 31, 2025 | -114.61% |
| Sep 30, 2025 | -122.78% |
| Jun 30, 2025 | -164.12% |
| Mar 31, 2025 | -158.60% |
| Dec 31, 2024 | -143.99% |
| Sep 30, 2024 | -113.91% |
| Jun 30, 2024 | -87.43% |
| Mar 31, 2024 | -66.38% |
| Dec 31, 2023 | -64.72% |
| Sep 30, 2023 | -56.56% |
| Jun 30, 2023 | -55.38% |
| Mar 31, 2023 | -109.78% |
| Dec 31, 2022 | -92.39% |
| Sep 30, 2022 | -80.24% |
| Jun 30, 2022 | -59.43% |
| Mar 31, 2022 | -20.69% |
| Dec 31, 2021 | -17.90% |
| Sep 30, 2021 | -14.31% |